NO20001684L - Metoder og sammensetninger for Õ indusere tumor-spesifikk cytotoksisitet - Google Patents

Metoder og sammensetninger for Õ indusere tumor-spesifikk cytotoksisitet

Info

Publication number
NO20001684L
NO20001684L NO20001684A NO20001684A NO20001684L NO 20001684 L NO20001684 L NO 20001684L NO 20001684 A NO20001684 A NO 20001684A NO 20001684 A NO20001684 A NO 20001684A NO 20001684 L NO20001684 L NO 20001684L
Authority
NO
Norway
Prior art keywords
methods
compositions
induce tumor
specific cytotoxicity
sequences
Prior art date
Application number
NO20001684A
Other languages
English (en)
Other versions
NO328470B1 (no
NO20001684D0 (no
Inventor
Abraham Hochberg
Suhail Ayesh
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Publication of NO20001684D0 publication Critical patent/NO20001684D0/no
Publication of NO20001684L publication Critical patent/NO20001684L/no
Publication of NO328470B1 publication Critical patent/NO328470B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
NO20001684A 1997-10-03 2000-03-31 Vektor for a uttrykke en sekvens i en tumorcelle og vertcelle omfattende denne, samt fremgangsmater for a uttrykke sekvensen in vitro og anvendelse av vektoren for fremstilling av et medikament for behandling av cancer. NO328470B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94360897A 1997-10-03 1997-10-03
PCT/IL1998/000486 WO1999018195A2 (en) 1997-10-03 1998-10-04 Methods and compositions for inducing tumor-specific cytotoxicity

Publications (3)

Publication Number Publication Date
NO20001684D0 NO20001684D0 (no) 2000-03-31
NO20001684L true NO20001684L (no) 2000-06-02
NO328470B1 NO328470B1 (no) 2010-02-22

Family

ID=25479934

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20001684A NO328470B1 (no) 1997-10-03 2000-03-31 Vektor for a uttrykke en sekvens i en tumorcelle og vertcelle omfattende denne, samt fremgangsmater for a uttrykke sekvensen in vitro og anvendelse av vektoren for fremstilling av et medikament for behandling av cancer.
NO20093194A NO331723B1 (no) 1997-10-03 2009-10-22 Vektor som kan utrykke et cytotoksisk genprodukt samt anvendelse av en slik vektor for fremstilling av et preparat for behandling av kreft

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20093194A NO331723B1 (no) 1997-10-03 2009-10-22 Vektor som kan utrykke et cytotoksisk genprodukt samt anvendelse av en slik vektor for fremstilling av et preparat for behandling av kreft

Country Status (17)

Country Link
US (2) US6087164A (no)
EP (1) EP1019499B1 (no)
JP (3) JP5153031B2 (no)
KR (1) KR100524262B1 (no)
CN (1) CN1229496C (no)
AT (1) ATE407948T1 (no)
AU (1) AU755774B2 (no)
BR (1) BR9812717B1 (no)
CA (1) CA2308124C (no)
CZ (2) CZ294941B6 (no)
DE (1) DE69840001D1 (no)
HU (1) HU228470B1 (no)
IL (1) IL135430A0 (no)
NO (2) NO328470B1 (no)
PL (1) PL339949A1 (no)
RU (1) RU2214280C2 (no)
WO (1) WO1999018195A2 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040006220A1 (en) * 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of insulin-like growth factor 2 expression
US7041654B2 (en) 1997-10-03 2006-05-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
DE19956568A1 (de) * 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
CA2365901A1 (en) * 1999-04-14 2000-10-19 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
DE19928342A1 (de) * 1999-06-21 2000-12-28 Deutsches Krebsforsch Vektoren zur gentherapeutischen Tumorbehandlung
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
WO2002046449A2 (en) * 2000-12-07 2002-06-13 The Penn State Research Foundation Selection of catalytic nucleic acids targeted to infectious agents
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US20040005567A1 (en) * 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of cyclin-dependent kinase 4 expression
AU2003241985A1 (en) * 2002-05-31 2003-12-19 Medinet Co., Ltd. Dna inducing cancer cell-specific expression and cancer cell-specific expression vector
US20040180844A1 (en) * 2003-03-10 2004-09-16 Fesik Stephen W. Method of killing cancer cells
US20040220085A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Compositions for nucleic acid delivery
US20040219099A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Method for the treatment of tumors
US7482156B2 (en) * 2003-10-15 2009-01-27 Cell Genesys, Inc. Hepatocellular carcinoma specific promoter and uses thereof
US7063947B2 (en) * 2004-04-08 2006-06-20 Promogen, Inc. System for producing synthetic promoters
US7429482B2 (en) * 2005-01-13 2008-09-30 United States Of America As Represented By The Department Of Veterans Affairs Screening tools for discovery of novel anabolic agents
EP1915448B1 (en) 2005-07-07 2013-09-04 Yissum Research Development Company, of The Hebrew University of Jerusalem Nucleic acid agents for downregulating h19, and methods of using same
DE602006014009D1 (de) 2005-09-22 2010-06-10 Yissum Res Dev Co Nukleinsäure konstrukten, pharmazeutische kompositionen und methoden für die behandlung von krebs
CA2675967A1 (en) * 2007-01-16 2008-07-24 Yissum Research Development Company Of The Hebrew University Of Jerusale M Nucleic acid constructs and methods for specific silencing of h19
CA2715080C (en) 2007-09-28 2021-09-28 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
WO2009053982A1 (en) * 2007-10-25 2009-04-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Constructs containing multiple expression cassettes for cancer therapy
EP2298866A4 (en) * 2008-07-02 2013-11-20 Otsuka Pharma Co Ltd ARTIFICIAL KIDNEY PRECURSOR AND METHOD FOR PRODUCING THE SAME
US8492133B2 (en) 2009-01-20 2013-07-23 Ramot At Tel Aviv University, Ltd. MIR-21 promoter driven targeted cancer therapy
EA016223B1 (ru) * 2009-10-07 2012-03-30 Учреждение Российской Академии Наук Институт Молекулярной Генетики Ран Способ и генная конструкция для высокоспецифичного ингибирования нежелательного роста клеток
WO2016178233A1 (en) * 2015-05-05 2016-11-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Nucleic acid-cationic polymer compositions and methods of making and using the same
BR112020021962A2 (pt) * 2018-04-30 2021-01-26 Amicus Therapeutics, Inc. construtos para terapia gênica e métodos de uso
CN110714075B (zh) * 2018-07-13 2024-05-03 立森印迹诊断技术（无锡）有限公司 一种用于检测肺肿瘤良恶性程度的分级模型及其应用
CN111206093A (zh) * 2018-11-21 2020-05-29 立森印迹诊断技术（无锡）有限公司 一种用于检测浸润性膀胱癌的标志物及其应用
CN109609505A (zh) * 2019-01-14 2019-04-12 中国科学院成都生物研究所 一种体内筛选的剪切rna的锤头状核酶

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2699191B1 (fr) * 1992-12-16 1995-02-10 Univ Paris Curie Nouveaux vecteurs rétroviraux, lignées cellulaires les contenant, et leur utilisation dans le traitement des tumeurs.
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
IL108879A (en) * 1994-03-07 2000-08-31 Yissum Res Dev Co Diagnostic assay for malignancies using the H19 gene and kit
FR2723697B1 (fr) * 1994-08-17 1996-09-20 Rhone Poulenc Rorer Sa Methode de traitement de la restenose par la therapie genique
FR2725213B1 (fr) * 1994-10-04 1996-11-08 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation en therapie genique

Also Published As

Publication number Publication date
WO1999018195A3 (en) 1999-08-12
AU755774B2 (en) 2002-12-19
EP1019499A2 (en) 2000-07-19
BR9812717A (pt) 2000-08-22
DE69840001D1 (de) 2008-10-23
CA2308124A1 (en) 1999-04-15
WO1999018195A2 (en) 1999-04-15
ATE407948T1 (de) 2008-09-15
JP2001519148A (ja) 2001-10-23
IL135430A0 (en) 2001-05-20
HUP0003745A2 (hu) 2001-02-28
CZ294941B6 (cs) 2005-04-13
CZ20001201A3 (cs) 2000-09-13
BR9812717B1 (pt) 2011-06-28
NO328470B1 (no) 2010-02-22
JP2008136480A (ja) 2008-06-19
JP5153031B2 (ja) 2013-02-27
RU2214280C2 (ru) 2003-10-20
JP2006304801A (ja) 2006-11-09
HUP0003745A3 (en) 2002-04-29
NO20093194L (no) 2000-06-02
CZ294694B6 (cs) 2005-02-16
KR100524262B1 (ko) 2005-10-28
HU228470B1 (en) 2013-03-28
NO331723B1 (no) 2012-03-05
AU9457198A (en) 1999-04-27
CN1229496C (zh) 2005-11-30
EP1019499B1 (en) 2008-09-10
US6306833B1 (en) 2001-10-23
CN1280616A (zh) 2001-01-17
US6087164A (en) 2000-07-11
CA2308124C (en) 2008-07-08
KR20010030912A (ko) 2001-04-16
PL339949A1 (en) 2001-01-15
NO20001684D0 (no) 2000-03-31

Similar Documents

Publication Publication Date Title
NO20001684D0 (no) Metoder og sammensetninger for Õ indusere tumor-spesifikk cytotoksisitet
HK1030019A1 (en) Recombinational cloning using nucleic acids havingrecombination sites
ZA988124B (en) Mage-3 peptides presented by HLA class II molecules
BR9407956A (pt) Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais
FI972225A0 (fi) Vektorit kudosspesifistä replikaatiota varten
GR3035936T3 (en) Histidine and homohistidine derivatives as inhibitors of protein farnesyltransferase
GR3031234T3 (en) Therapeutically useful peptides and peptides fragments
WO1997022695A3 (fr) Sequences nucleotidiques, proteines, medicaments et agents diagnostiques utiles dans le traitement du cancer
FI940375A0 (fi) Peptidit, joilla on elimiä suojaavaa vaikutusta, menetelmä niiden valmistamiseksi ja niiden käyttö terapiassa
NZ504938A (en) Tumor antigen peptide derivatives capable of binding to HLA-A24 antigen
HK1008347A1 (en) Dorsal tissue affecting factor and compositions
AU7154901A (en) Replication deficient adenoviral tnf vector
RU2487165C2 (ru) Конструкции, содержащие составные экспрессионные кассеты, для терапии рака
EP1070122A4 (en) INDUCTION OF THE EXPRESSION OF APOPTOTIC OR CYTOTOXIC GENES BY CO-SUPPORT OF ADENOVIRAL MEDIATED GENES
IL126152A0 (en) Recombinant adenoviral vectors for human tumor gene therapy
ZA200202413B (en) Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression.
PT1007717E (pt) Processos e composicoes para terapias do cancro,utilizando genes que codificam o interferao-beta
MX2023006869A (es) Proteinas de union condicionalmente biespecificas.
WO2001027256A3 (en) Chimeric transcriptional regulatory element and methods for prostate-targeted gene expression
ES2164011A1 (es) Uso combinado de la quimiocina ip-10 y la interleucina-12 en la preparacion de composiciones para el tratamiento de tumores malignos.
WO2000078939A3 (de) Vektoren zur gentherapeutischen tumorbehandlung
AU3941002A (en) Cyp1b1 nucleic acids and methods of use
AU1879097A (en) Fragments of cr1 and their use
WO2001087934A3 (en) Treatment of neoplasia/transformation using a pituitary tumor transforming gene carboxy terminal peptides
PL315670A1 (en) Expression of heterological proteins in attenuated bacteria with use of htra promoters

Legal Events

Date Code Title Description
MK1K Patent expired